SynthesisPediatric nephrology (Berlin, Germany)2026
Diagnostic accuracy of serum cystatin C for pediatric acute kidney injury: a systematic review and meta-analysis.
Synthesis in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly and accurate detection of acute kidney injury (AKI) in children is difficult because serum creatinine rises late and lacks sensitivity. Serum cystatin C has been proposed as an earlier biomarker, but pediatric evidence has been inconsistent.
methodsWe performed a systematic review and meta-analysis of studies evaluating serum cystatin C for pediatric acute kidney injury. PubMed, Cochrane Library, Scopus, and Web of Science were searched from inception through June 2025. Eligible studies compared cystatin C against standardized AKI definitions (KDIGO, pRIFLE, or AKIN) and reported sufficient diagnostic accuracy data. Two reviewers independently screened, extracted, and assessed study quality using QUADAS-2. Pooled estimates of sensitivity and specificity were calculated using a bivariate random effects model with hierarchical summary receiver operating characteristic curves. Subgroup and meta-regression analyses explored sources of heterogeneity. Certainty of evidence was assessed with GRADE-DTA. The review was registered with PROSPERO (CRD420251104342).
resultsTwenty-six studies comprising 3742 pediatric patients were included. Pooled sensitivity was 78.2% (95% CI 72.6-82.9) and specificity was 79.5% (95% CI 73.5-84.5), with an area under the curve of 0.854, reflecting good overall discriminatory power. Predictive values varied with disease prevalence: at 10% prevalence, the negative predictive value reached 97.0%, while at 40% prevalence, the positive predictive value increased to 71.8%. Bayesian meta-regression identified clinical setting as a significant effect modifier, with higher accuracy in ward-based studies compared with pediatric intensive care unit cohorts. Sensitivity analyses confirmed robustness, and no evidence of publication bias was detected. Certainty of evidence was rated moderate for sensitivity and specificity and high for area under the curve.
conclusionsSerum cystatin C is a reliable biomarker for early pediatric AKI detection, offering superior performance to creatinine and particularly strong rule-out value in lower-prevalence settings. Its clinical utility would be enhanced by standardized cut-offs, cost-effectiveness evaluation, and integration into biomarker panels.
Indexed as
Identifiers
41636794What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.